Genome And Company Enters Clinical Trial Collaboration With Msd To Evaluate 'Gen-001' In Combo With Keytruda In Phase 2 Trial In Biliary Tract Cancer Patients

Genome And Company Enters Clinical Trial Collaboration With Msd To Evaluate 'Gen-001' In Combo With Keytruda In Phase 2 Trial In Biliary Tract Cancer Patients

By, Admin 7 March 2022

Genome And Company, A Leading Global Microbiome Anti-Cancer Drug Development Company, Has Entered Into A First Clinical Trial Collaboration And Supply Agreement (Ctcsa) With Msd (A Tradename Of Merck & Co., Inc., Kenilworth, N.J., Usa). Upon The Execution Of The Agreement, Genome And Company Will Conduct A Phase 2 Clinical Trial To Evaluate The Safety And Efficacy Of Its Immuno-Oncology Microbiome Therapeutic, 'Gen-001', In Combination With Msd'S Anti-Pd-1 Therapy, Keytruda (Pembrolizumab), In Patients With Biliary Tract Cancer. Genome And Company Will Be The Sponsor Of The Clinical Trial And Msd Will Supply Keytruda.'Gen-001' Is An Orally Administered Immuno-Oncology Microbiome Therapeutic Candidate Consisting Of Lactococcus Lactis (L. Lactis), A Single Live Bacterial Strain Isolated From A Healthy Human.Biliary Tract Cancer Is One Of The Carcinomas Associated With A Poor Prognosis After Diagnosis, Limited Treatment Options And Five-Year Survival Rate Of Only 5 To 15%. According To The Findings In The Mdpi Cancers 2021, An Sci Academic Journal, The Infiltrations Of Immune Cells Around Cancer Cells Were Observed In 70% Of Biliary Tract Cancer Patients, Also Confirming The Relationship Between The Immune Cells And Biliary Tract Cancer Cells.Dr. Jisoo Pae, Ceo Of Genome And Company, Said, "Genome And Company Has Established Clinical Trial Collaborations To Evaluate 'Gen-001' With Both Anti-Pd-L1 And Anti-Pd-1 Therapies Through Agreements With Msd, Merck Kgaa, Darmstadt, Germany And Pfizer, Which Shows That The Company Is Being Recognized For Its Innovative Technology By Global Immuno-Oncology Companies." He Added, "Through This Clinical Trial Collaboration, We Look Forward To Evaluating The Potential Additive Benefit Of 'Gen-001' In Combination With Keytruda As Treatment For Patients With Biliary Tract Cancer."

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!